Reset filter
Nyckelord
Augenheilkunde ×
Visa mer Nyckelord
Innehållsförteckning
  1. 1. Klinisk studie
  2. 2. Rutindokumentation
  3. 3. Register- och kohortstudier
  4. 4. Kvalitetssäkring
  5. 5. Datastandard
  6. 6. Frågeformulär för patienter
  7. 7. Medicinsk specialitet
Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

595 Sökresultat.
Relevans Bedömning Nya först Gamla först

Pharmacodynamics urine- 1-dehydrothromboxane B2 (PDU) day 1 Pazopanib Macular Degeneration MD1103367 - Pharmacodynamics urine- 1-dehydrothromboxane B2 (PDU) day 1

- 2018-07-02 - 1 Formulär, 1 Item-grupp, 2 Dataelement, 1 Språk
Item-grupp: Pharmacodynamics urine; pre-treatment
Study part: Pharmacodynamics urine- 1-dehydrothromboxane B2 (PDU), day 1. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

Concomitant Medications (Con Med) Pazopanib Macular Degeneration MD1103367 - Concomitant Medications (Con Med)

- 2018-07-02 - 1 Formulär, 1 Item-grupp, 12 Dataelement, 1 Språk
Item-grupp: Concomitant Medications
Study part: Concomitant Medications (Con Med). A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

Logs and Repeats (Logs/Rpts) Pazopanib Macular Degeneration MD1103367 - Logs and Repeats (Logs/Rpts)

- 2018-07-02 - 1 Formulär, 2 Item-grupper, 7 Dataelement, 1 Språk
Item-grupper: Date of visit, Adverse Event; concomitant medication; questions
Study part: Logs and Repeats (Logs/Rpts). A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

Adverse Event (AE) Pazopanib Macular Degeneration MD1103367 - Adverse Event

- 2018-06-24 - 1 Formulär, 1 Item-grupp, 16 Dataelement, 1 Språk
Item-grupp: Adverse Event
Study part: Adverse Event. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

Pharmacokinetics Blood GW786034 Follow- up Pazopanib Macular Degeneration MD1103367 - Pharmacokinetics Blood GW786034 Follow- up

- 2018-06-20 - 1 Formulär, 1 Item-grupp, 2 Dataelement, 1 Språk
Item-grupp: Pharmacokinetics blood; follow- up
Study part: Pharmacokinetics Blood GW786034 Follow- up. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

12 Lead ECG- Follow-up Pazopanib Macular Degeneration MD1103367 - 12 Lead ECG- Follow-up

- 2018-06-20 - 1 Formulär, 1 Item-grupp, 8 Dataelement, 1 Språk
Item-grupp: 12 Lead ECG; Follow- up
Study part: 12 Lead ECG- Follow-up. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

Treatment confirmation Pazopanib Macular Degeneration MD1103367 - Treatment confirmation

- 2018-06-20 - 1 Formulär, 1 Item-grupp, 2 Dataelement, 1 Språk
Item-grupp: Treatment confirmation
Study part: Treatment confirmation. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

SF- 36 Health Survey Day 0 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2598g - SF- 36 Health Survey Day 0

- 2018-06-20 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: SF- 36 Health Survey
Study part: SF- 36 Health Survey Day 0. A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) In Subjects With Minimally Classic Or Occult Subfoveal Neovascular Age-Related Macular Degeneration.

Pregnancy Information Pazopanib Macular Degeneration MD1103367 - Pregnancy Information

- 2018-06-19 - 1 Formulär, 2 Item-grupper, 2 Dataelement, 1 Språk
Item-grupper: Pregnancy Information male, Pregnancy Information female
Study part: Pregnancy Information. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

Clinical Chemistry- Coagulation (COAG) Pazopanib Macular Degeneration MD1103367 - Clinical Chemistry- Coagulation (COAG)

- 2018-06-17 - 1 Formulär, 1 Item-grupp, 10 Dataelement, 1 Språk
Item-grupp: Coagulation factor measurement
Study part: Clinical Chemistry- Coagulation (COAG). A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

Urinalysis Protein (Lab Uri_Pro) Pazopanib Macular Degeneration MD1103367 - Urinalysis Protein (Lab Uri_Pro)

- 2018-06-17 - 1 Formulär, 1 Item-grupp, 11 Dataelement, 1 Språk
Item-grupp: urinalysis protein
Study part: Urinalysis Protein (Lab Uri_Pro). A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

Clinical Chemistry Pitutary Coagulation GnRH Pazopanib Macular Degeneration MD1103367 - Clinical Chemistry Pitutary Coagulation GnRH

- 2018-06-17 - 1 Formulär, 3 Item-grupper, 20 Dataelement, 1 Språk
Item-grupper: Pituitary/adrenal hormone measurement, Coagulation factor measurement, Gonadotropin Releasing Hormone Measurement
Study part: Clinical Chemistry- Pitutary Coagulation GnRH. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial